What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
For Compounding Pharmacies
Compounding pharmacy procurement runs on documentation, not catalog browsing. PeptideXpo's release packet, batch-specific COA, HPLC chromatogram, ESI mass spec, water content, counter-ion, plus LAL endotoxin and USP <61>/<62> microbial limits on request, is built to match the documentation standards 503A state boards and 503B FDA registration actually look for.
Why compounding pharmacies choose PeptideXpo
Every batch ships with a Certificate of Analysis identified by lot number, manufacturing date, and re-test date. The COA covers the standard analytical scope (HPLC purity, ESI mass spec within 0.5 Da of theoretical, Karl Fischer water content, counter-ion content) plus optional add-ons for injectable workflows: bacterial endotoxin (LAL per USP <85>), microbial limits (USP <61>/<62>), and stability data on the specific lot.
Acetate is the default counter-ion across the catalog, not TFA. Residual TFA suppresses observed potency in cell-based assays and is not pharmaceutically acceptable in most finished formulations, so we route every standard-spec peptide through ion-exchange to deliver acetate-salt material. TFA-salt is available on explicit request for the narrow research workflows that need it.
Our regulatory team responds to destination-market questions in writing, typically within 24 business hours. For US-bound material, that means awareness of the current 503A and 503B regulatory state, the July 2026 PCAC review of seven peptides under consideration for the 503A bulks list, and the documentation expectations under each pathway. We won't dispense legal advice, but we can describe how our documentation depth aligns with the operational standards.
Cold-chain logistics throughout, validated insulated packaging, continuous temperature monitoring, and DDP shipping to most major markets. The temperature record is part of the released-batch documentation chain so your in-house QA has the data for receipt acceptance.
Sample COA on every shipment
Sequence + MS verification for sensitive APIs
Tamper-evident, customs-compliant packaging
FDA 503A documentation alignment
Regions served: USA · Canada · EU
Curated catalog
The peptides most commonly procured by 503A and 503B compounding pharmacies in our buyer base.
GIP / GLP-1 dual receptor agonist
GIP / GLP-1 / glucagon tri-agonist
GLP-1 receptor agonist
Long-acting amylin analog
15-mer
Body Protection Compound 15-mer
43-mer
Thymosin β4 fragment
BPC-157 + TB-500 repair-stack blend
4-mer
Pineal gland tetrapeptide
Frequently asked
The standard packet for compounding-pharmacy procurement includes: batch-specific COA, HPLC chromatogram with peak integration, ESI mass spec confirming molecular weight, water content by Karl Fischer, counter-ion identification (acetate by default), bacterial endotoxin (LAL per USP <85>), and USP <61>/<62> microbial limits. Sequence verification by LC-MS/MS is included for any peptide >15 residues. Stability data on the specific lot is available on request. The released-batch documentation also includes the cold-chain temperature record from shipping.
Yes. 503B procurement requires deeper supplier-audit support beyond the standard COA, including manufacturing-facility audit history, raw-material supplier verification, change-control documentation, and stability data on the actual lot. We extend the documentation scope on request to match 503B expectations. Discuss the specific 503B requirements at quote stage so the analytical scope and audit-support package match your facility's quality system.
PCAC will evaluate seven peptides for 503A bulks-list inclusion in July 2026: BPC-157, TB-500, KPV, MOTS-c, Emideltide, Semax, Epitalon. If FDA accepts PCAC's recommendation, 503A compounding pharmacies could legally use these peptides for patient-specific compounding under standard 503A documentation requirements. Regardless of the PCAC outcome, the documentation depth buyers demand has structurally shifted upward, suppliers without auditable analytical packets will not survive the next two procurement cycles. Our documentation is already aligned with the post-PCAC standards.
State boards of pharmacy vary substantially in their enforcement of 503A compounding rules. Some states (Florida, Texas, Arizona) operate with more permissive frameworks; others (California, several Northeast states) apply stricter enforcement. The same compounded preparation that's clearly permissible in one state may face regulatory scrutiny in another. We don't provide state-specific legal advice, but our regulatory team can describe the documentation depth that supports your specific state-board interaction. Match your procurement to your state's current framework, not to a uniform federal expectation.
Yes. Established compounding-pharmacy buyers can negotiate recurring-order pricing against forecasted quarterly or annual volume, with PeptideXpo holding released-batch inventory against the forecast to compress effective lead time. The forecasting model works best when the buyer can commit to 4-8 weeks of forward visibility on order timing; in exchange, lead time on releases drops from the standard 7-21 days to next-available-shipment. Discuss the procurement schedule at quote stage to set up the inventory arrangement.
Related reading
A first reply within 24 hours · Catalog · Sample COA · MOQ · Lead time. Our regulatory and sales teams read every inquiry before any price goes out.
